Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
$78,000 |
 |
AmarinAMRN |
$520,000 |
 |
Gilead SciencesGILD |
-$2B |
 |
Anavex Life SciencesAVXL |
-$6.3M |
 |
AmgenAMGN |
-$109M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Burroughs Amy L. | Jan 15, 2026 | Sell | 61,228 | $37.0153 | $2.3M |
| Burroughs Amy L. | Jan 15, 2026 | Sell | 7,521 | $37.5256 | $280,000 |
| Burroughs Amy L. | Jan 5, 2026 | Sell | 71,339 | $38.103 | $2.7M |
| Kuriakose Emil | Jan 2, 2026 | Sell | 955 | $38.3586 | $37,000 |
| Kuriakose Emil | Jan 2, 2026 | Sell | 200 | $39.6 | $7,900 |
| Quigley Jill M. | Nov 4, 2025 | Sell | 24,520 | $18 | $440,000 |
| Kuriakose Emil | Oct 1, 2025 | Sell | 944 | $7.8464 | $7,400 |
| Kuriakose Emil | Jul 1, 2025 | Sell | 853 | $4.2671 | $3,600 |
| Gengos Andrew | Jun 27, 2025 | Buy | 5,000 | $3.9299 | $20,000 |
| Burroughs Amy L. | Jun 25, 2025 | Buy | 23,314 | $3.8702 | $90,000 |
| Gengos Andrew | Jun 16, 2025 | Buy | 5,000 | $3.9465 | $20,000 |
| Kuriakose Emil | Apr 1, 2025 | Sell | 952 | $2.4851 | $2,400 |
| Vignola Mark J. | Jan 6, 2025 | Sell | 9,059 | $5.7953 | $52,000 |
| Quigley Jill M. | Jan 6, 2025 | Sell | 8,760 | $5.7943 | $51,000 |
| Kuriakose Emil | Jan 2, 2025 | Sell | 4,481 | $5.7146 | $26,000 |
| Vignola Mark J. | Jan 2, 2025 | Sell | 8,129 | $5.7232 | $47,000 |
| Quigley Jill M. | Jan 2, 2025 | Sell | 6,240 | $5.7215 | $36,000 |
| Burroughs Amy L. | Dec 5, 2024 | Buy | 15,450 | $7.15 | $110,000 |
| Jung Melita Sun | Nov 30, 2024 | Buy | 2,250 | $5.11 | $11,000 |
| Burroughs Amy L. | Nov 30, 2024 | Buy | 510 | $5.11 | $2,600 |
| Lu Hongbo | Sep 12, 2024 | Buy | 285,714 | $10.5 | $3M |
| Lu Hongbo | Sep 12, 2024 | Buy | 190,476 | $10.5 | $2M |
| Vignola Mark J. | Sep 10, 2024 | Sell | 10,000 | $11 | $110,000 |
| Quigley Jill M. | Sep 9, 2024 | Sell | 17,235 | $10 | $170,000 |
| Quigley Jill M. | Aug 2, 2024 | Sell | 8,857 | $7.5005 | $66,000 |
| Quigley Jill M. | Aug 1, 2024 | Sell | 6,143 | $7.6751 | $47,000 |
| GORDON CARL L | Jul 16, 2024 | Sell | 4,009 | $10 | $40,000 |
| ORBIMED ADVISORS LLC | Jul 16, 2024 | Sell | 4,009 | $10 | $40,000 |
| Quigley Jill M. | Jul 16, 2024 | Sell | 400 | $10 | $4,000 |
| GORDON CARL L | Jul 16, 2024 | Sell | 623 | $10 | $6,200 |
| GORDON CARL L | Jul 16, 2024 | Sell | 556 | $10 | $5,600 |
| ORBIMED ADVISORS LLC | Jul 16, 2024 | Sell | 623 | $10 | $6,200 |
| ORBIMED ADVISORS LLC | Jul 16, 2024 | Sell | 556 | $10 | $5,600 |
| Quigley Jill M. | Jul 15, 2024 | Sell | 14,365 | $10.0007 | $140,000 |
| GORDON CARL L | Jul 15, 2024 | Sell | 39,433 | $10 | $390,000 |
| ORBIMED ADVISORS LLC | Jul 15, 2024 | Sell | 39,433 | $10 | $390,000 |
| GORDON CARL L | Jul 15, 2024 | Sell | 6,142 | $10 | $61,000 |
| GORDON CARL L | Jul 15, 2024 | Sell | 5,401 | $10 | $54,000 |
| ORBIMED ADVISORS LLC | Jul 15, 2024 | Sell | 6,142 | $10 | $61,000 |
| ORBIMED ADVISORS LLC | Jul 15, 2024 | Sell | 5,401 | $10 | $54,000 |
| Yoon Seokho Bryan | May 31, 2024 | Buy | 4,791 | $4.44 | $21,000 |
| Vignola Mark J. | May 31, 2024 | Buy | 4,791 | $4.44 | $21,000 |
| Vivo Capital Fund VIII, L.P. | Apr 3, 2024 | Sell | 103,870 | $6.2 | $640,000 |
| Vivo Capital Fund VIII, L.P. | Apr 3, 2024 | Sell | 30,047 | $6.2 | $190,000 |
| Vivo Capital Fund VIII, L.P. | Apr 3, 2024 | Sell | 4,149 | $6.2 | $26,000 |
| Vivo Capital Fund VIII, L.P. | Apr 2, 2024 | Sell | 76,346 | $6.65 | $510,000 |
| Vivo Capital Fund VIII, L.P. | Apr 2, 2024 | Sell | 22,084 | $6.65 | $150,000 |
| Vivo Capital Fund VIII, L.P. | Apr 2, 2024 | Sell | 3,050 | $6.65 | $20,000 |
| Vivo Capital Fund VIII, L.P. | Apr 1, 2024 | Sell | 136,255 | $6.99 | $950,000 |
| Vivo Capital Fund VIII, L.P. | Apr 1, 2024 | Sell | 39,411 | $6.99 | $280,000 |
| Vivo Capital Fund VIII, L.P. | Apr 1, 2024 | Sell | 5,451 | $6.99 | $38,000 |
FAQ - Insider Transactions
The most recent insider transaction for Terns Pharmaceuticals was conducted by Burroughs Amy L., who sold 61,228 shares on January 15, 2026 at a price of $37.02 per share.
Lu Hongbo has bought the most TERN stock in the last 2 years, with a total value of $5M.
Burroughs Amy L. has sold the most TERN stock in the last 2 years, with a total value of $5.3M.
The total value of insider transactions for Terns Pharmaceuticals in the last 2 years is negative, amounting to -$5.1M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
Over the last 2 years, insider transactions for Terns Pharmaceuticals have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
